EYPT EyePoint, Inc.

NASDAQ

$3.62

EyePoint, Inc. (EYPT) Earnings News

Earnings press releases, previews and reviews for EyePoint, Inc. (EYPT), newest first.

Monday August 17, 2026 7:00 AM ET

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

Wednesday August 5, 2026 7:00 AM ET

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Thursday July 30, 2026 7:00 AM ET

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

Monday July 13, 2026 7:00 AM ET

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Thursday May 14, 2026 7:00 AM ET

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

Wednesday May 6, 2026 7:00 AM ET

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wednesday April 29, 2026 7:00 AM ET

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026